Comparison of cytomorphology and histomorphology in myelodysplastic syndromes

被引:0
作者
Nachtkamp, Kathrin [1 ]
Strupp, Corinna [1 ]
Faoro, Rosa [1 ]
Gattermann, Norbert [1 ]
Dietrich, Sascha [1 ]
Germing, Ulrich [1 ]
Baldus, Stefan [2 ]
机构
[1] Heinrich Heine Univ, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[2] Heinrich Heine Univ, Dept Pathol, Dusseldorf, Germany
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
myelodysplastic syndromes; cytomorphology; histopathology; prognosis; WHO2022; WORLD-HEALTH-ORGANIZATION; MARROW FIBROSIS; CLASSIFICATION; PROPOSALS;
D O I
10.3389/fonc.2024.1359115
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gold standard for the establishment of the diagnosis of myelodysplastic syndromes (MDS) are cytomorphological features of hematopoietic cells in peripheral blood and bone marrow aspirates. There is increasing evidence that bone marrow histomorphology not only aids in the diagnosis of MDS but can provide additional prognostic information, particularly through assessment of fibrosis and cellularity. However, there is only sparse data on direct comparison between histological and cytomorphological findings within the same MDS patient cohort. Therefore, we performed such an analysis under exceptionally well-standardized conditions. We reexamined biopsy material of 128 patients from the D & uuml;sseldorf MDS registry who underwent bone marrow trephine biopsy (in addition to bone marrow aspiration) at the time of diagnosis, addressing the following items: a. Analysis of concordance of diagnoses made by histology and cytomorphology b. Analysis of additional information by histology with regard to the diagnosis and prognosis. The respective biomaterials were available at our institution and had been processed according to unchanged protocols between 1992 and 2010. Fresh histopathological sections were obtained from the tissue blocks, stained under identical conditions and re-assessed by a designated expert pathologist (C.B.) without knowledge of the previous histopathological report or the respective cytomorphological diagnosis. The latter, likewise, was uniformly made by the same expert cytomorphologist (U.G.). Histopathology of bone marrow trephine biopsies reliably captured the diagnosis of MDS. Assignment to the diagnostic WHO subgroup was not entirely concordant with cytomorphology, mainly due to incongruences between the proportion of CD34-positive cells on histopathology and the cytomorphological blast count. Histopathology provided additional diagnostic and prognostic information with high diagnostic and prognostic significance, such as fibrosis. Likewise, histopathology allowed more reliable estimation of bone marrow cellularity.
引用
收藏
页数:10
相关论文
共 17 条
  • [1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [2] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) : 189 - 199
  • [3] Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
    Bono, Elisa
    McLornan, Donal
    Travaglino, Erica
    Gandhi, Shreyans
    Galli, Anna
    Khan, Alesia Abigael
    Kulasekararaj, Austin G.
    Boveri, Emanuela
    Raj, Kavita
    Elena, Chiara
    Ireland, Robin M.
    Bianchessi, Antonio
    Jiang, Jie
    Todisco, Gabriele
    Ferretti, Virginia Valeria
    Cazzola, Mario
    Marsh, Judith C. W.
    Malcovati, Luca
    Mufti, Ghulam J.
    [J]. LEUKEMIA, 2019, 33 (10) : 2495 - 2505
  • [4] Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS
    Bruck, Oscar E.
    Lallukka-Bruck, Susanna E.
    Hohtari, Helena R.
    Ianevski, Aleksandr
    Ebeling, Freja T.
    Kovanen, Panu E.
    Kytola, Soili, I
    Aittokallio, Tero A.
    Ramos, Pedro M.
    Porkka, Kimmo, V
    Mustjoki, Satu M.
    [J]. BLOOD CANCER DISCOVERY, 2021, 2 (03): : 238 - 249
  • [5] Brunning RD., 2008, WHO CLASSIFICATION T, V4tH ed lARC, P87
  • [6] Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes
    Buesche, G.
    Teoman, H.
    Wilczak, W.
    Ganser, A.
    Hecker, H.
    Wilkens, L.
    Goehring, G.
    Schlegelberger, B.
    Bock, O.
    Georgii, A.
    Kreipe, H.
    [J]. LEUKEMIA, 2008, 22 (02) : 313 - 322
  • [7] Prognostic value of circulating CD34+ cells in myelodysplastic syndromes
    Cesana, Clara
    Klersy, Catherine
    Brando, Bruno
    Nosari, Annamaria
    Scarpati, Barbara
    Scampini, Linda
    Molteni, Alfredo
    Nador, Guido
    Santoleri, Luca
    Formenti, Marta
    Valentini, Marina
    Mazzone, Antonino
    Morra, Enrica
    Cairoli, Roberto
    [J]. LEUKEMIA RESEARCH, 2008, 32 (11) : 1715 - 1723
  • [8] Myelodysplastic syndromes and bone marrow microenvironment
    Della Porta, Matteo Giovanni
    [J]. LEUKEMIA RESEARCH, 2011, 35 (11) : 1442 - 1443
  • [9] Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
    Fattizzo, Bruno
    Serpenti, Fabio
    Barcellini, Wilma
    Caprioli, Chiara
    [J]. CANCERS, 2021, 13 (01) : 1 - 20
  • [10] Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients
    Germing, U
    Gattermann, N
    Strupp, C
    Aivado, M
    Aul, C
    [J]. LEUKEMIA RESEARCH, 2000, 24 (12) : 983 - 992